News
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced four
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T System, a Tumor Treating Fields (TTFields)
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO® (abrocitinib), an oral
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO® (abrocitinib), an oral
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences.
Frank D’Amelio, Chief
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences.
Frank D’Amelio, Chief
Savara to Participate in Two Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On September 2
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), a Phase 3 clinical trial evaluating the efficacy
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), a Phase 3 clinical trial evaluating the efficacy
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare
Novocure Appoints Bill Burke as Chief Human Resources Officer
Novocure (NASDAQ: NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:
-
2021 Virtual
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key
Pfizer Announces New Chief Business Innovation Officer
Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer’s Executive
Pfizer Announces New Chief Business Innovation Officer
Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer’s Executive
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture